Opthea Limited (AU:OPT) has released an update.
Opthea Limited, a biopharmaceutical firm, is set to present key findings from its Phase 2 and ongoing Phase 3 clinical trials of sozinibercept at the Retina World Congress 2024. The company’s CEO, Frederic Guerard, will join a panel discussion, and experts will provide insights into the potential of sozinibercept to improve treatment for wet age-related macular degeneration. These presentations underscore Opthea’s commitment to addressing the unmet needs in retinal diseases through innovative therapies.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
